Salbutamol dry-powder inhalation - Alkermes

Drug Profile

Salbutamol dry-powder inhalation - Alkermes

Alternative Names: AlbuLast; Albuterol dry-powder inhalation - Alkermes

Latest Information Update: 01 Jun 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alkermes
  • Developer Advanced Inhalation Research; Alkermes
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 01 Jun 2006 No development reported - Phase-II for Asthma in USA (Inhalation)
  • 10 Feb 2003 This programme is still in active development
  • 26 Jul 2000 Phase-II clinical trials for Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top